Live Breaking News & Updates on Kent Tseng

Stay updated with breaking news from Kent tseng. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model


Share:
SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ( Company ) announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19. The group plans on submitting the publication to a peer review journal.
Dr. Chien-Te Kent Tseng, Professor of the Department of Microbiology and Immunology and Director of GNL s SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: In our hamster COVID-19 model, pulmonary inflammation with cellular infiltrates and hemorrhage (mild-to-moderate) is triggered by SARS-CoV-2 infection. Treatme ....

United States , Aleksandrak Drelich , Ronald Moss , Dennisj Carlo , Kempaiah Rayavara , Mark Flather , Kent Tseng , Adamis Pharmaceuticals Corporation , Compounding Inc , Adamis Pharmaceuticals , University Of Texas Medical Branch , Galveston National Laboratory , Corporate Communications , Professor Of The Department Microbiology , Stanford University , Pharmaceuticals Corporation , Texas Medical Branch , Chien Te Kent Tseng , Acute Respiratory Distress Syndrome , Placebo Controlled Study , Chief Medical Officer , Chief Executive Officer , Bi Hung Peng , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ரொனால்ட் பாசி ,

COVID-19: Angina drug may be an effective treatment


COVID-19: Angina drug may be an effective treatment
Written by Erika Watts on February 26, 2021 Fact checked by Hilary Guite, FFPH, MRCGP
New research in cells shows the drug bepridil holds promise for treating COVID-19. filadendron/Getty Images
A recent study shows that bepridil a drug approved by the Food and Drug Administration (FDA) for treating heart angina but currently voluntarily withdrawn due to cardiac side effects may be highly effective in treating COVID-19.
The researchers tested 55 different FDA-approved medications. As many as 29 of these showed promise, and six were found to reduce activity of a crucial enzyme that helps the virus replicate. ....

United States , University Of Texas , Wenshe Ray Liu , Kent Tseng , University Of Texas Medical Branch At Galveston , Texasam University , Drug Administration , College Station , National Academy , Gradipore Chair , Chien Te Kent Tseng , Texas Medical Branch , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் , கேண்ட் ட்செங் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் மருத்துவ கிளை இல் கால்வெஸ்டன் , கல்லூரி நிலையம் , தேசிய கலைக்கழகம் , சீன் தே கேண்ட் ட்செங் , டெக்சாஸ் மருத்துவ கிளை ,

Texas A&M: Texas A&M-UTMB Team Identifies Potential Drug To Treat SARS-CoV-2


Share
A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).
The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.
The team’s leaders are College of Science professor Wenshe Ray Liu, professor and holder of the Gradipore Chair in the Department of Chemistry at Texas A&M, and Chien-Te Kent Tseng, professor and director of the SARS/MERS/COVID-19 Laboratory at UTMB. Liu also holds joint faculty positions in Texas A&M’s colleges of medicine and agriculture and life sciences. ....

United States , University Of Texas , Chia Chuan Cho , Kacic Kratch , Drakem Mellott , Jasonc Hsu , Wenshe Ray Liu , Kais Yang , Shiqing Xu , Erolc Vatansever , Aleksandrak Drelich , Kempaiah Rayavara , Kent Tseng , Texasam University , College Of Science , Drug Administration , College Of Agriculture , Department Of Biochemistry , Texasam Translational Investment Fund , University Of Texas Medical Branch , Department Of Chemistry At Texas , Department Of Chemistry , Excellence Fund , European Medicines Agency , Life Sciences , Texas Medical Branch ,